Bayer, Orion to start Phase III trials for prostate cancer drug

pharmafile | June 3, 2016 | News story | Medical Communications, Research and Development, Sales and Marketing Bayer, drug trial, orion, prostate cancer, research 

German pharma and crop sciences giant Bayer (ETR: BAYN) and Orion Corp (Nasdaq Helsinki: ORNAV) have agreed to start a Phase III trial for the drug compound to treat prostate cancer.

The trial, which will start this year, will evaluate the safety and efficacy of the compound in combination with standard androgen deprivation therapy (ADT) and the chemotherapy docetaxel.

In 2014, Orion and Bayer entered into a global partnership for the compound, which was later expanded to include the joint development of the drug ODM-201 (BAY-1841788) for metastatic hormone-sensitive prostate cancer.

The trial drug is currently in Phase III study for high-risk non-metastatic castration-resistant prostate cancer.

Orion is eligible to receive milestone payments from Bayer upon achievement of certain ODM-201 related development, tech transfer and commercialization milestones, as well as substantial royalties on future sales. In addition, Orion will be responsible for manufacturing of the product.

Prostate cancer is the second most common form of cancer worldwide and the fifth leading cause of cancer-related death in men. More than 1.1 million men worldwide were diagnosed with the disease in 2012.

Anjali Shukla

Related Content

Bayer and Aignostics to collaborate for AI oncology research

Bayer and Aignostics have announced that they have entered into a strategic collaboration for several …

national-cancer-institute-kmvohcb-w5g-unsplash_1

First patient dosed in AdvanCell’s phase 1/2 trial for prostate cancer treatment

AdvanCell has announced that the first patient has been dosed with 212Pb-ADVC001 in its phase …

BMS shares new research and development  plans at the company’s R&D day

Bristol Myers Squibb (BMS) recently held a Research and Development (R&D) Day in New York, …

Latest content